| Autor: |
Buffet, Camille, Allard, Lucie, Guillerm, Erell, Ghander, Cécile, Mathy, Elise, Lussey-Lepoutre, Charlotte, Julien, Nicolas, Touma, Eliane, Quilhot, Pauline, Godiris-Petit, Gaelle, Lacorte, Jean-Marc, Leenhardt, Laurence, Denis, Jérôme Alexandre |
| Předmět: |
|
| Zdroj: |
European Journal of Endocrinology; Sep2022, Vol. 187 Issue 3, pK33-K38, 6p |
| Abstrakt: |
Introduction: Recently, targeted therapies using BRAFV600E and MEK inhibitors (dabrafenib and trametinib, respectively) have been recommended in BRAF-mutated anaplastic thyroid carcinoma (ATC). Considering the fast development of ATC, droplet digital PCR (ddPCR) performed on fine-needle aspirate (FNA), which is a rapid, reliable, and low-cost method, appears interesting for the detection of BRAFV600E mutation in these patients and allows early initiation of targeted therapies. Results: In our two patients, both presenting extensive cervical masses inaccessible to surgery, ddPCR results were available in less than 24 h. Therefore, dabrafenib and trametinib were started only a few days after first contact. Conclusions: We suggest that ddPCR on FNA be used in non-resectable cervical masses for rapid BRAFV600E mutation detection in the hope that starting targeted therapies early might improve outcomes. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
